Effect of treatment on lipids and markers of inflammation
| Variable | Allocation | Baseline | Year 1 | Paired p value | One-year changes |
|---|---|---|---|---|---|
| hsCRP (mg/L) | Treatment | 2.1 (0.9–4.1)* | 1.2 (0.6–2.4)* | <0.001 | 1.76 (0.0–4.4)** |
| Placebo | 2.2 (0.9–4.9) | 1.8 (0.85–4.35) | 0.003 | 0.00 (−1.5–2.1) | |
| Total cholesterol (mmol/L) | Treatment | 5.72 (5.05–6.42) | 3.39 (2.95–3.91)** | <0.001 | 2.25 (1.7–2.8)** |
| Placebo | 5.67 (4.97–6.37) | 5.5 (4.92–6.2) | <0.001 | 0.13 (−0.3–0.5) | |
| LDL-cholesterol (mmol/L) | Treatment | 3.49 (2.94–4.15) | 1.32 (1.02–1.69)** | <0.001 | 2.13 (1.6–2.6)** |
| Placebo | 3.46 (2.92–4.08) | 3.34 (2.81–3.92) | <0.001 | 0.12 (−0.2–0.4) | |
| White cell count (109/L) | Treatment | 5.72 (5.05–6.42) | |||
| Placebo | 5.8 (4.9–6.9) | ||||
| AST (U/L) | Treatment | 16 (14–19) | 19 (16–23)** | <0.001 | −3.20 (−5.0–0.0)** |
| Placebo | 16 (14–19) | 16 (14–19) | 0.59 | 0.00 (−2.0–2.0) |
Between groups (allocation): *p<0.05; **p<0.001.
Data are shown as median values and IQR. One-year changes are shown at baseline minus year 1 values.
AST, aspartate aminotransferase; hsCRP, high-sensitive C reactive protein; LDL, low-density lipoproteins.